Vera Therapeutics, Inc. - VERA STOCK NEWS

Vera Therapeutics, Inc. announced positive interim data from its Phase 2b ORIGIN clinical trial of atacicept in IgA Nephropathy (IgAN), revealing a 41% mean reduction in proteinuria for the 150mg dose group at 24 weeks. The company plans to start a Phase 3 clinical trial in Q2 2023 and expects to release 36-week data from ORIGIN then. Vera reported a net loss of $89.1 million for 2022, increasing from $32.6 million in the previous year. Despite this, it has a strong balance sheet with approximately $188 million from recent follow-on offerings, supporting operations through early 2026.

Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company, will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference in Boston from March 6 – 8, 2023. The chat is scheduled for March 6 at 2:10 PM ET and will be available via webcast. Additionally, the management team will hold one-on-one investor meetings at the event. Vera focuses on developing transformative treatments for serious immunological diseases, with its lead product candidate, atacicept, targeting conditions like IgA nephropathy and lupus nephritis. A replay of the event will be accessible for 90 days on their website.

On February 6, 2023, Vera Therapeutics (NasdaqGM: VERA) announced the successful closing of its underwritten public offering of 16,428,572 shares of Class A common stock at a price of $7.00 per share. This transaction, which includes the full exercise of the underwriters' option to purchase an additional 2,142,857 shares, is expected to generate gross proceeds of approximately $115 million before expenses. J.P. Morgan, Cowen, and Evercore ISI led the offering, which was conducted under an effective shelf registration statement. Vera focuses on transformative treatments for serious immunological diseases, including its lead product candidate, atacicept.

Vera Therapeutics, Inc. (NasdaqGM: VERA) has priced its public offering of 14,285,715 shares of Class A common stock at $7.00 per share, aiming to raise gross proceeds of $100 million. A 30-day option for underwriters to purchase an additional 2,142,857 shares is included. The offering is set to close on February 6, 2023, pending customary conditions. The initiative is supported by a shelf registration statement declared effective on June 13, 2022. Vera focuses on transformative treatments for serious immunological diseases, with candidates like atacicept and MAU868 in its pipeline.

Vera Therapeutics, a late-stage biotechnology company, has announced a public offering of $75 million shares of its Class A common stock, aimed at developing treatments for serious immunological diseases. The offering is subject to market conditions, with underwriters being granted a 30-day option to purchase an additional 15% of the shares. J.P. Morgan, Cowen, and Evercore ISI are the joint book-running managers. Vera's lead candidate, atacicept, targets autoimmune diseases including IgA nephropathy and lupus nephritis, while MAU868 addresses BK Virus infections. The offering will be conducted under a shelf registration statement and the company holds full rights to its drug candidates.

Vera Therapeutics focuses on advancing atacicept, a promising treatment for IgA nephropathy, into a pivotal Phase 3 trial in 1H 2023. Recent results from the Phase 2b ORIGIN trial showed a 47% mean reduction in proteinuria at Week 36 for the 150 mg atacicept group versus baseline, indicating significant efficacy. The drug was well-tolerated, with a 1% discontinuation rate due to adverse events. Vera plans to extend its cash runway to Q4 2024 while prioritizing resources for the upcoming pivotal trial. Full data will be showcased at medical congresses, with a focus on further informing the Phase 3 trial design.

Innocoll Holdings Ltd. has appointed Kimball Hall as President and Chief Executive Officer, bringing over 30 years of experience in commercial operations. Hall will also lead Innocoll's subsidiaries, Syntacoll GmbH and Innocoll Biotherapeutics Inc., focusing on expanding their services and product offerings. Previously, Hall served as President and COO at Abzena, overseeing multiple manufacturing sites. Gurnet Point Capital, Innocoll's parent company, expressed confidence in Hall’s ability to drive growth, particularly in non-opioid pain management products like Xaracoll® and Posimir®.

Vera Therapeutics (Nasdaq: VERA) has announced an upcoming virtual key opinion leader (KOL) event featuring Dr. Jonathan Barratt from the University of Leicester. The event will provide updates on atacicept’s ORIGIN Phase 2b data focused on IgA nephropathy (IgAN). Atacicept is a dual inhibitor aimed at treating IgAN, a serious autoimmune kidney disease. The ORIGIN trial involves 116 patients testing the efficacy and safety of atacicept against a placebo. Primary endpoints include changes in proteinuria at 24 weeks. The company aims to address the high unmet medical need in IgAN treatment, leveraging data from this and future trials.